-
RareAction Network > FDA
Archives
1-7 of 7 items
July 12, 2017
Washington, D.C., July 12, 2017 – The National Health Council (NHC) and the National Organization for Rare Disorders (NORD) commend the House of Representatives for passing the FDA Reauthorization Act (FDARA) […]
NORD Issues Statement on the FDA’s Orphan Drug Modernization Plan
June 29, 2017
Washington, D.C., June 29, 2017 — The following statement was issued today by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), following the FDA’s announcement of its […]
September 23, 2016
Unanimous vote extends the Rare Pediatric Disease Priority Review Voucher Program with important policy changes through December Washington, D.C., September 23, 2016 – On Thursday, the Senate reached an important compromise […]
NORD Responds to AHIP Report on Orphan Drug Act
September 2, 2016
By Peter L. Saltonstall One of the most successful pieces of legislation ever passed by the Congress is the Orphan Drug Act of 1983 (ODA). It was intended to stimulate […]
NORD Issues Statement in Response to PDUFA VI Commitment Letter
July 21, 2016
On July 15, the Food and Drug Administration released the performance goals letter for the reauthorization of the Prescription Drug User Fee Act, also known as PDUFA VI. The PDUFA program […]
NORD Issues Statement as Senate Postpones Vote on Cures Legislation
July 14, 2016
The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), as the Senate announced it would not vote on its […]
Today, Tell Congress We Need #CuresNow
June 7, 2016
Today, June 7, join rare disease advocates around the country and tell your Senators to support the Senate Cures Legislation. This month is the last chance for Senate Cures to pass […]
1-7 of 7 items
Quick Search
Subscribe
Blog Categories
Archives
